Navigation Links
ArmaGen® Re-engineers Erythropoietin for Brain Penetration
Date:7/16/2010

LOS ANGELES, July 16 /PRNewswire/ -- Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport. ArmaGen Technologies has developed the BBB molecular Trojan horse platform technology for solving the BBB drug delivery problem, and has used this technology to create a brain penetrating form of human EPO. ArmaGen® has successfully re-engineered human EPO as an IgG fusion protein that penetrates the brain following intravenous (IV) administration. Human EPO is fused to a genetically engineered monoclonal antibody (MAb) to the human insulin receptor (HIR). The HIRMAb acts as a molecular Trojan horse to ferry the EPO across the BBB via transport on the endogenous BBB insulin receptor. The HIRMAb-EPO fusion protein is a dual receptor specific protein with low nM binding constants for both the human EPO receptor and the human insulin receptor. The HIRMAb part of the HIRMAb-EPO fusion protein cross-reacts with the Rhesus monkey insulin receptor. Therefore, brain penetration of the HIRMAb-EPO fusion protein was demonstrated in vivo in the adult Rhesus monkey following IV administration.  EPO alone was shown not to cross the primate BBB. The brain uptake of the HIRMAb-EPO fusion protein in the Rhesus monkey is high, 2% injected dose/brain, and comparable to the brain uptake of small molecules. The plasma pharmacokinetics (PK) of the HIRMAb-EPO fusion protein differs markedly from the PK of EPO, which minimizes any effect of the fusion protein on erythropoiesis. EPO-driven neuroprotection in human brain disorders is now possible with systemic administration of the HIRMAb-EPO fusion protein at doses that have minimal effects on erythropoiesis. The work is published in the June, 2010 issue of the Journal of Pharmacology and Experimental Therapeutics.

About ArmaGen® Technologies

ArmaGen® Technologies is a privately-held biotechnology company developing therapeutic products for the central nervous system. ArmaGen® re-engineers recombinant proteins to enable transport across the BBB. With ArmaGen®'s proprietary molecular Trojan horse technology, any recombinant protein can be re-engineered as a new brain penetrating neuropharmaceutical. For more information on ArmaGen® Technologies, visit the Company's Web site at www.armagen.com.


'/>"/>
SOURCE ArmaGen Technologies
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anemic Patients With MDS Gain Long-Term Benefits From Erythropoietin and Myeloid Growth Factor Hormones
2. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
3. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
4. Unprecedented Donation Made by Mrs. Lily Safra to the Institute for Brain and Spinal Cord Disorders in Paris
5. Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elektas Leksell Gamma Knife Perfexion
6. Brainlab Collaborates With Toshiba Medical Systems on Integrated Surgical Suite
7. Kendle Advances Early Stage Drug Development with ElMindAs Innovative Brain Network Activation Technology
8. Gamma Knife Users Share Latest Advances for Treating Cancer, Other Brain Disorders at Society Meeting in Greece
9. Elekta Opens a New Window into Human Brain Activity, Focuses on Brain Mets at 2010 AANS Meeting
10. Karolinska University Hospital Acquires Leksell Gamma Knife Perfexion to Expand Radiosurgery Versatility, Efficiency in Brain Cancer Therapy
11. Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... LONDON , Dec. 6, 2016 ... report provides in-depth region wise and country wise ... this report include manufacturers of human vaccines products, ... players planning to enter the market. The ... global human vaccines market. Qualitative analysis comprises market ...
(Date:12/6/2016)... Dec. 6, 2016 Eurofins Genomics today ... the College of American Pathologists (CAP) and certification ... its new laboratory in Louisville, KY ... North American headquarters. "Our new CLIA-licensed ... which is still considered the ,Gold Standard, method ...
(Date:12/6/2016)... , Dec. 6, 2016  BTL Aesthetics today ... that its BTL Vanquish ME device was effectively ... delivery to the targeted tissue. The result: Significantly ... higher, with BTL Vanquish ME versus BTL Vanquish. ... physician network and their patients with the most ...
Breaking Medicine Technology:
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... The medical ... holidays and winter seasons. One major study analyzing heart attacks among 138,602 people ... August of a given year. We would all agree of course–no time of year ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite is honored to be ... Best New Product Launch category. Gensuite’s entry on their EZ Scan feature detailed ... Events & Training Group is a professional event and training provider based in ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, LA.c., a certified ... Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility ... patients realize their family building goals. Acupuncture helps fertility patients by ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a brief ... the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation of ... can for this country. , Nancy attributes her patriotic nature to her WWII veteran ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... “Fred Rides ... sweet Christmas Day that follows. , “Fred Rides a Train” is the creation ... and short stories since her teen years in Michigan. The "Fred, the Dog" series ...
Breaking Medicine News(10 mins):